Mylan Ireland Ltd Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MYLAN IRELAND LTD, and when can generic versions of MYLAN IRELAND LTD drugs launch?
MYLAN IRELAND LTD has four approved drugs.
There are twenty US patents protecting MYLAN IRELAND LTD drugs.
There are sixty-four patent family members on MYLAN IRELAND LTD drugs in thirty-one countries and one supplementary protection certificate in one country.
Summary for Mylan Ireland Ltd
| International Patents: | 64 |
| US Patents: | 20 |
| Tradenames: | 4 |
| Ingredients: | 4 |
| NDAs: | 4 |
Drugs and US Patents for Mylan Ireland Ltd
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mylan Ireland Ltd | YUPELRI | revefenacin | SOLUTION;INHALATION | 210598-001 | Nov 9, 2018 | RX | Yes | Yes | 10,550,081 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Mylan Ireland Ltd | YUPELRI | revefenacin | SOLUTION;INHALATION | 210598-001 | Nov 9, 2018 | RX | Yes | Yes | 7,550,595 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Mylan Ireland Ltd | YUPELRI | revefenacin | SOLUTION;INHALATION | 210598-001 | Nov 9, 2018 | RX | Yes | Yes | 11,247,969 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Mylan Ireland Ltd | YUPELRI | revefenacin | SOLUTION;INHALATION | 210598-001 | Nov 9, 2018 | RX | Yes | Yes | 7,288,657 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Mylan Ireland Ltd | PRETOMANID | pretomanid | TABLET;ORAL | 212862-001 | Aug 14, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
| Mylan Ireland Ltd | MIACALCIN | calcitonin salmon | INJECTABLE;INJECTION | 017808-002 | Mar 29, 1991 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Mylan Ireland Ltd
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Mylan Ireland Ltd | ARIXTRA | fondaparinux sodium | INJECTABLE;SUBCUTANEOUS | 021345-001 | Dec 7, 2001 | 4,818,816 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Mylan Ireland Ltd Drugs
Supplementary Protection Certificates for Mylan Ireland Ltd Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0084999 | 2002C/012 | Belgium | ⤷ Sign Up | PRODUCT NAME: FONDAPARINUX SODIQUE; REGISTRATION NO/DATE: EU/1/02/206/001 20020321 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
